Prevention of Recurrent Symptomatic Urinary Tract Infections in Patients with Chronic Neurogenic Bladder Dysfunction: A mixed Method Study (The PReSUTINeB Study).
Active, no longer recruiting
Phase of Trial: Phase III/IV
Latest Information Update: 17 Jan 2018
At a glance
- Drugs Escherichia-coli-strains (Primary)
- Indications Urinary tract infections
- Focus Therapeutic Use
- Acronyms The PReSUTINeB Study
- 15 Jan 2018 Planned End Date changed from 1 Sep 2017 to 31 Dec 2018.
- 15 Jan 2018 Status changed from completed to active, no longer recruiting.
- 04 Sep 2017 Status changed from active, no longer recruiting to completed.